TY - JOUR
T1 - Enhanced Oxidative Stress and Other Potential Biomarkers for Retinopathy in Type 2 Diabetics
T2 - Beneficial Effects of the Nutraceutic Supplements
AU - Roig-Revert, María J.
AU - Lleó-Pérez, Antonio
AU - Zanón-Moreno, Vicente
AU - Vivar-Llopis, Bárbara
AU - Marín-Montiel, Juan
AU - Dolz-Marco, Rosa
AU - Alonso-Muñoz, Luis
AU - Albert-Fort, Mara
AU - López-Gálvez, María I.
AU - Galarreta-Mira, David
AU - García-Esparza, María F.
AU - Galbis-Estrada, Carmen
AU - Marco-Ramirez, Carla
AU - Shoaie-Nia, Kian
AU - Sanz-González, Silvia M.
AU - Vila-Bou, Vicente
AU - Bendala-Tufanisco, Elena
AU - García-Medina, José J.
AU - Nucci, Carlo
AU - Gallego-Pinazo, Roberto
AU - Arévalo, J. Fernando
AU - Pinazo-Durán, Maria D.
N1 - Publisher Copyright:
© 2015 María J. Roig-Revert et al.
PY - 2015
Y1 - 2015
N2 - We have studied the global risk of retinopathy in a Mediterranean population of type 2 diabetes mellitus (T2DM) patients, according to clinical, biochemical, and lifestyle biomarkers. The effects of the oral supplementation containing antioxidants/omega 3 fatty acids (A/ω3) were also evaluated. Suitable participants were distributed into two main groups: (1) T2DMG (with retinopathy (+DR) or without retinopathy (-DR)) and (2) controls (CG). Participants were randomly assigned (+A/ω3) or not (-A/ω3) to the oral supplementation with a daily pill of Nutrof Omega (R) for 18 months. Data collected including demographics, anthropometrics, characteristics/lifestyle, ophthalmic examination (best corrected visual acuity, ocular fundus photographs, and retinal thickness as assessed by optical coherence tomography), and blood parameters (glucose, glycosylated hemoglobin, triglycerides, malondialdehyde, and total antioxidant capacity) were registered, integrated, and statistically processed by the SPSS 15.0 program. Finally, 208 participants (130 diabetics (68 +DR/62 -DR) and 78 controls) completed the follow-up. Blood analyses confirmed that the T2DMG+DR patients had significantly higher oxidative stress (p < 0.05), inflammatory (p < 0.05), and vascular (p < 0.001) risk markers than the T2DMG-DR and the CG. Furthermore, the A/ω3 oral supplementation positively changed the baseline parameters, presumptively by inducing metabolic activation and ameliorating the ocular health after 18 months of supplementation.
AB - We have studied the global risk of retinopathy in a Mediterranean population of type 2 diabetes mellitus (T2DM) patients, according to clinical, biochemical, and lifestyle biomarkers. The effects of the oral supplementation containing antioxidants/omega 3 fatty acids (A/ω3) were also evaluated. Suitable participants were distributed into two main groups: (1) T2DMG (with retinopathy (+DR) or without retinopathy (-DR)) and (2) controls (CG). Participants were randomly assigned (+A/ω3) or not (-A/ω3) to the oral supplementation with a daily pill of Nutrof Omega (R) for 18 months. Data collected including demographics, anthropometrics, characteristics/lifestyle, ophthalmic examination (best corrected visual acuity, ocular fundus photographs, and retinal thickness as assessed by optical coherence tomography), and blood parameters (glucose, glycosylated hemoglobin, triglycerides, malondialdehyde, and total antioxidant capacity) were registered, integrated, and statistically processed by the SPSS 15.0 program. Finally, 208 participants (130 diabetics (68 +DR/62 -DR) and 78 controls) completed the follow-up. Blood analyses confirmed that the T2DMG+DR patients had significantly higher oxidative stress (p < 0.05), inflammatory (p < 0.05), and vascular (p < 0.001) risk markers than the T2DMG-DR and the CG. Furthermore, the A/ω3 oral supplementation positively changed the baseline parameters, presumptively by inducing metabolic activation and ameliorating the ocular health after 18 months of supplementation.
UR - http://www.scopus.com/inward/record.url?scp=84947233488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947233488&partnerID=8YFLogxK
U2 - 10.1155/2015/408180
DO - 10.1155/2015/408180
M3 - Article
C2 - 26618168
AN - SCOPUS:84947233488
SN - 2314-6133
VL - 2015
JO - BioMed research international
JF - BioMed research international
M1 - 408180
ER -